Matching Articles
Back to the Disease Index
Ophthalmology: Bacterial Conjunctivitis
Results 1 to 2 of 2 articles.
Ophthalmic Besifloxacin (Besivance)
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009 (Issue 1327)
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
http://secure.medicalletter.org/TML-article-1327e | Show Introduction Hide Introduction
Ophthalmic Azithromycin (AzaSite)
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
The FDA has approved azithromycin 1% ophthalmic solution (AzaSite - Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a controlled-release delivery system that keeps the drug in the eye for several hours.
http://secure.medicalletter.org/TML-article-1279b | Show Introduction Hide Introduction
